# Blood DNA Methylation Biomarkers of Alzheimer's Disease > **NIH NIH R01** · UNIVERSITY OF WISCONSIN-MADISON · 2021 · $594,887 ## Abstract Project Summary Recent array-based epigenome-wide association studies (EWAS) of brain tissue report differential DNA methylation in known and newly recognized late-onset sporadic Alzheimer’s disease (LOAD) genes, thereby underscoring the utility of EWAS in disclosing novel genes and pathways associated with LOAD pathogenesis. As an alternative to the study of samples from donor brains, investigation of DNA methylation in accessible peripheral tissues offers the opportunity to improve LOAD diagnosis and prognosis. Recently, we’ve identified differentially methylated positions (DMPs) in blood that distinguish men and women with and without LOAD at 477 of 769,190 loci in a plurality of genes. Of these DMPs, 17 are shared between DMPs observed using clinical LOAD markers analyzed independently as continuous variables comprising Rey Auditory Verbal Learning Test scores, cerebrospinal fluid total tau (t-tau) and phosphorylated tau 181 (p-tau181) levels, and t-tau/Aβ1–42 (Aβ42), p-tau181/Aβ42, and Aβ42/Aβ1–40 (Aβ40) ratios. In patients with LOAD, 12 of the shared 17 DMPs are hypo- methylated in B3GALT4 (Beta-1,3-galatcosyltransferase 4), a gene previously associated with LOAD in superior temporal gyrus brain tissue, and 5 are hypo-methylated in ZADH2 (Prostaglandin reductase 3), a novel LOAD- associated gene. Together these data reinforce use of blood to identify DMPs associated with dementia that arises from LOAD, leading to the hypothesis that DNA methylation levels in blood may be used to identify novel diagnostic, prognostic, and modifiable therapeutic targets of LOAD. Using a whole-genome-based approach, this proposal builds upon the Wisconsin Alzheimer’s Disease Research Center’s (WADRC) existing banked biofluids and phenotypic data to validate the 477 DMPs, including sites in B3GALT4 and ZADH2, as biomarkers of LOAD, while at the same time examining DNA methylation levels across the entire human genome (>25 million loci), with the potential to further identify novel DNA methylation predictors of LOAD. In addition, these studies will be expanded by examining a second cohort of female and male participants presently enrolled in the WADRC with and without mild cognitive impairment (MCI) to identify DNA methylation biomarkers prior to the onset of LOAD. MCI is an intermediate stage between cognitively normal older adults and LOAD. Patients with MCI have an elevated risk of progressing to dementia. Eighty percent of MCI patients convert to LOAD after an average of 6 years. Blood biomarkers that distinguish patients with MCI who later progress to LOAD from those with MCI who do not progress to LOAD offer a substantial opportunity to improve the diagnosis and early intervention in patients with accelerated cognitive aging. Together, findings from the present proposal will provide the foundation for identifying DNA methylation profiles in blood that predict the expression and progression to LOAD, detect deviations from healthy cognitive trajectories, ide... ## Key facts - **NIH application ID:** 10216168 - **Project number:** 5R01AG066179-02 - **Recipient organization:** UNIVERSITY OF WISCONSIN-MADISON - **Principal Investigator:** Reid Spencer Alisch - **Activity code:** R01 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2021 - **Award amount:** $594,887 - **Award type:** 5 - **Project period:** 2020-07-15 → 2025-04-30 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/10216168 ## Citation > US National Institutes of Health, RePORTER application 10216168, Blood DNA Methylation Biomarkers of Alzheimer's Disease (5R01AG066179-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10216168. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*